中文Vientiane, Laos - September 22, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative
treatments for cancer, announced today that Cabozantinib products has been approved by the Lao Ministry of Health.
Approved drugs are:
Cabozantinib: Sold under the brand name CABODX, it is an oral small molecule tyrosine kinase inhibitor (tyrosine kinase inhibitor, TKI). Cabozantinib, as a TKI,
can effectively inhibit targets including MET, AXL, VEGFR-1, VEGFR-2, and VEGFR-3. These targets are involved in a series of processes related to tumor
occurrence and development, such as tumor angiogenesis, invasion, metastasis and drug resistance.
About Big Bear Pharma
Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse
pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of
patients with cancer by providing them with more options, better outcomes and lower costs.
Forward-Looking Statements
To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release
are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from
actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in
clinical research results, exposure to various market risks, and other factors beyond the control of the company.